mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction Clinical Trial

Official title: A Randomized, Parallel Control Trial to Compare mFOLFOX Versus mFOLFIRI Versus FOLFPTX (a Combination of Paclitaxel, Fluorouracil) as First-line Treatment in Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

Status Not yet recruiting

Clinical Trial Summary

The aim of this study was to compare the efficacy and safety of mFOLFOX, mFOLFIRI and FOLFPTX as first-line treatment in AGC or EGJA.

Clinical Trial Description

In previous studies, we found that mFOLFOX(a Combination of Oxaliplatin, Fluorouracil), mFOLFIRI(a Combination of Irinotecan, Fluorouracil), FOLFPTX (a Combination of Paclitaxel, Fluorouracil) are active in patients with AGC or EGJA.This study is being done to find out which one has the best efficacy. ;

Related Conditions & MeSH terms

• Adenocarcinoma
• Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
• Stomach Neoplasms

• NCT number: NCT03045770
• Study type: Interventional
• Source: Fujian Cancer Hospital
• Contact: Jianwei Yang
• Phone: 008613805097959
• Email: swzcq62@163.com
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 10, 2017
• Completion date: December 30, 2019